In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. 5 June 2019. Charles Rhyee.

Executive Summary

Digital health still sparks excitement, but also a healthy dose of caution. Charles Rhyee, an analyst at New York-based investment bank Cowen, says investors who were around in the early 2000s have seen a lot of hype, but also understand that dynamics have changed, including the reimbursement and regulatory environments. Check out his comments here.

"There is a lot of excitement [about digital health] but also a healthy level of caution. You will see the avid growth investor wants to see a higher bar and they will look at rates of adoption and the reimbursement environment." – Charles Rhyee, senior research analyst, Cowen

Click here for a free trial of Medtech Insight
 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel